Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1781-1782, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haliassos, A.
Right arrow Articles by Terzoglou, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haliassos, A.
Right arrow Articles by Terzoglou, G.
Related Collections
Right arrow Oak Ridge Conference
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 1997;43:1781-1782.)
© 1997 American Association for Clinical Chemistry, Inc.

Oak Ridge Poster Sessions

Use of Anti-Xa Activity as a Marker for Heparin-Induced Bleeding in Patients with APTT >180 s

Alexander Haliassosa, Helen Melita-Manolis, Despina Aggelaki, Despina Tassi and George Terzoglou

Clin. Labs., Onassis Cardiac Surgery Center, 356 Syngrou Ave., GR-176 74 Kallithea, Greece
a author for correspondence: fax + 301 93 06 604, e-mail mdb1@hol.gr

Heparin is administered as an anticoagulant in treatment of or prophylaxis against arterial or venous thromboembolism, in treatment of myocardial infarction, and during cardiac surgery (cardiopulmonary bypass) (1), coronary angioplasty, and other procedures (2).

Heparin treatment demands laboratory control and is monitored by determining the activated partial thromboplastin time (APTT), which should be adjusted to stay within 1.5–2 times the control value (3). Sometimes during therapy high APTT values (>180 s) are reached (4), and physicians decide to interrupt the treatment for a few hours because of the great risk of hemorrhagic complications, the most important side effect of heparin therapy (5). In these situations, however, the true concentrations of heparin in the patient's plasma are really unknown. Moreover, in some described cases, the APTT values were prolonged because of underlying disease (severe liver disorders, extensive myocardial infarction, or infection) and postoperative complications after cardiac surgery (6). This prolongation of APTT was not heparin related, although the results of the APTT test falsely suggested a higher heparin concentration (7). Another problem is that sensitivity of the reagents for the APTT test varies greatly, and the physicians who prescribe heparin on the basis of certain APTT ratios may order different doses of heparin and . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.